Cormorant Asset Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Cormorant Asset Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,217,882	Closed	-$2.87M	–	68
2023 Q1	$2.87M	Hold	1,217,882	–	–	0.19%	57
2022 Q4	$2.78M	Sell	1,217,882 -5,618	-0.5%	-$13.9K	0.19%	59
2022 Q3	$3.38M	Sell	1,223,500 -81,595	-6%	-$260K	0.24%	55
2022 Q2	$3.18M	Hold	1,305,095	–	–	0.24%	58
2022 Q1	$5.14M	Hold	1,305,095	–	–	0.39%	51
2021 Q4	$5.75M	Hold	1,305,095	–	–	0.34%	54
2021 Q3	$8.06M	Sell	1,305,095 -110,405	-8%	-$772K	0.33%	59
2021 Q2	$11.2M	Hold	1,415,500	–	–	0.38%	59
2021 Q1	$15.1M	Hold	1,415,500	–	–	0.34%	59
2020 Q4	$21.4M	Buy	+1,415,500	New	+$27M	0.51%	46

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JMAC Enterprises Newtown, Pennsylvania $593M AUM 22.22% 1-Year Est. Return

Cormorant Asset Management's ELDN Position: Q2 2023 in Review

Cormorant Asset Management sold out of Eledon Pharmaceuticals (ELDN) in Q2 2023, closing a stake of 1,217,882 shares — an estimated $2.87M sold.

Cormorant Asset Management first reported a position in ELDN in Q4 2020 and held it in 10 quarters. The position peaked at $21.4M in Q4 2020. 33 funds tracked by Wall St. Rank hold ELDN as of Q2 2023.

Cormorant Asset Management reported no remaining Eledon Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Cormorant Asset Management sold 1,217,882 Eledon Pharmaceuticals shares in Q2 2023, an estimated $2.87M.
Cormorant Asset Management first reported a position in Eledon Pharmaceuticals in Q4 2020 and held it in 10 quarters.
Cormorant Asset Management's Eledon Pharmaceuticals position peaked at $21.4M in Q4 2020.
33 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2023.

Based on Cormorant Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.